US FDA approves Johnson & Johnson’s blood cancer therapy
Talvey will be sold at a list price of $45,000 per month
Johnson & Johnson said on Thursday the US Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.